These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15311562)

  • 1. Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
    Mysler E
    Int J Clin Pract; 2004 Jun; 58(6):606-11. PubMed ID: 15311562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.
    Atherton C; Jones J; McKaig B; Bebb J; Cunliffe R; Burdsall J; Brough J; Stevenson D; Bonner J; Rordorf C; Scott G; Branson J; Hawkey CJ
    Clin Gastroenterol Hepatol; 2004 Feb; 2(2):113-20. PubMed ID: 15017615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
    Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The second generation of COX-2 inhibitors: what advantages do the newest offer?
    Stichtenoth DO; Frölich JC
    Drugs; 2003; 63(1):33-45. PubMed ID: 12487621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
    Rordorf C; Kellett N; Mair S; Ford M; Milosavljev S; Branson J; Scott G
    Aliment Pharmacol Ther; 2003 Sep; 18(5):533-41. PubMed ID: 12950426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2 drug may help treat osteoarthritis.
    Health News; 2004 Dec; 10(12):13. PubMed ID: 15645573
    [No Abstract]   [Full Text] [Related]  

  • 9. The second generation of COX-2 inhibitors: clinical pharmacological point of view.
    Stichtenoth DO
    Mini Rev Med Chem; 2004 Aug; 4(6):617-24. PubMed ID: 15279595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
    Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
    Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects.
    Scott G; Yih L; Yeh CM; Milosavljev S; Laurent A; Rordorf C
    J Clin Pharmacol; 2004 Feb; 44(2):193-9. PubMed ID: 14747429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
    Bitner M; Kattenhorn J; Hatfield C; Gao J; Kellstein D
    Int J Clin Pract; 2004 Apr; 58(4):340-5. PubMed ID: 15161117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
    Rordorf CM; Choi L; Marshall P; Mangold JB
    Clin Pharmacokinet; 2005; 44(12):1247-66. PubMed ID: 16372823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumiracoxib.
    Buvanendran A; Barkin R
    Drugs Today (Barc); 2007 Mar; 43(3):137-47. PubMed ID: 17380211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumiracoxib.
    Lyseng-Williamson KA; Curran MP
    Drugs; 2004; 64(19):2237-46; discussion 2247-8. PubMed ID: 15456339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meloxicam: selective COX-2 inhibition in clinical practice.
    Furst DE
    Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
    Fox A; Medhurst S; Courade JP; Glatt M; Dawson J; Urban L; Bevan S; Gonzalez I
    Pain; 2004 Jan; 107(1-2):33-40. PubMed ID: 14715386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients.
    Andersen SJ
    Compr Ther; 2003; 29(4):215-23. PubMed ID: 14989043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.